DOI: 10.6084/m9.figshare.13379873
title: Metadata record for the manuscript: Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance

description: <b>Summary</b>This metadata record provides details of the data supporting the claims of the related manuscript: “Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance ”.The related study aimed to show that CLPTM1L (Cleft Lip and Palate Transmembrane protein 1-like) is broadly overexpressed and accumulated on the plasma membrane of ovarian tumor cells, while weakly or not expressed in normal tissues, and to demonstrate that in addition to cell-autonomous cytoprotection by CLPTM1L, extracellular CLPTM1L confers resistance to chemotherapeutic killing in an ectodomain-dependent fashion, and that this intercellular resistance mechanism is inhibited by anti-CLPTM1L biologics. Type of data: flow cytometry, immunohistochemistry, live cell imaging, cytotoxicity assaysSubject of data: A2780 parental and cisplatin resistant, Panc1, MiaPaCa2, CaPan2, A549, H226, and H520 human tumor. OVCAR4 and OVCAR5 cell line. MCW-OV-SL3 parental and cisplatin resistant cell lines derived from ovarian endometroid carcinoma patient of Department of Ob/Gyn at Medical College of Wisconsin. ID8 cells expressing luciferase. Fallopian tube epithelial cells FTE187 and FTE188. HeyA8. PeO1 and PeO4. <b>Data access</b>The majority of data are openly available as part of this metadata record. These files are listed below in line with the figures that they underlie in the related manuscript [in square brackets].<br>- [Figure 1]: Table S1, Ovarian and normal FDA panel IHC.xlsx- [Figure 2]: D01 A2780 unstained.fcs, D03 A2780 102-5.fcs, D04 A2780 secondary only.fcs, SL3 sensitive vs resistant cisplatin dose curves 5-30-19.pzfx, PEO4 HEYA8 OV5 Sen vs Res IC50.pzfx- [Figure 3]: A01 secondary only 102-5.fcs, A03 Vec unstained.fcs, A05 Vec 102-5.fcs, CRR9 and pretreated Supes gem cytoprotection 2-5-18.pzfx, A2780 102-5FL supe treatment chemoprotection 2-19-18.pzfx, A549 shCRR9 supe cytoprotection.pzfx, Main Figure 3F.xlsx- [Figure 4]: CLP supe 102-5 gem killing panc1.pzfx, dLoop exo chemosens 10-19-18.pzfx, dLoop Supe chemosens panc1 12-17.pzfx, serum exosomes 740 102-5 pretreatment carboplatin killing 5-1-19.pzfx- [Figure 5]: A01 ID8 unstained.fcs, A03 ID8 102-5.fcs, A04 ID8 secondary only.fcs, ID8 chemosens 102-1-5 10-29-18.pzfx, ESS102 ID8 autograft 10-18.pzfx, SL3 xenos 8-19.pzfx- [Supplementary Figure 2]: Supplementary Figure 2.pzfx- [Supplementary Figure 5]: Supplementary Figure-5.pzfx- [Supplementary Figure 6]: Supplementary Figure 6.xlsx Some of the data are not openly available due to intellectual property protection. These files may be available upon request to the corresponding author. These files are listed below in line with the supplementary figures they underlie.- [Supplementary Figure 1]: Supplementary Figure: 1g.pzf, 1h.pzf,1i.pzf- [Supplementary Figure 4]: Supplementary Figure: 4a.pzf, 4b.pzf, 4c.pzf, 4d.pzf Analyses were performed using GraphPad Prism 8 (GraphPad, La Jolla, CA, USA), Flowing Software 2 (Turku Bioimaging). <b>Corresponding author(s)</b><b></b>Dr. Michael James, Department of Surgery, Division of Research, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226; phone: +1(414)955-7572, (319) 400-7371; fax: +1(414)955-6059; e-mail: mjames@mcw.edu, mjames118@hotmail.comCo-corresponding author: Dr. Pradeep Chaluvally-Raghavan, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226. e-mail: pchaluvally@mcw.edu<br><br><b>Name of Institutional Review Board or ethics committee that approved the study</b>Medical College of Wisconsin, Milwaukee, USA. IACUC committee #2 under AUA6339.<b></b>